BMPR1A and Miyoshi myopathy: In their murine MM model, BMP signaling inhibition improved bone disease via anti-resorptive effects, attributed to blockade of BMPR1A-mediated pathways using a receptor antagonist (LDN193189) or BMPR1A-Fc ligand trap.